NGM Biopharmaceuticals Overview
- Year Founded
-
2008

- Status
-
Private
- Employees
-
158

- Latest Deal Type
-
PE Growth
- Financing Rounds
-
10
NGM Biopharmaceuticals General Information
Description
Operator of a biopharmaceutical company intended to translate complex, powerful biology with rigor and urgency into life-changing medicines. The company is engaged in developing novel therapeutics based on a scientific understanding of key biological pathways for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases, providing clients with medicines to treat persistent diseases and improve the well-being of their patients.
Contact Information
Website
www.ngmbio.comCorporate Office
- 333 Oyster Point Boulevard
- South San Francisco, CA 94080
- United States
Corporate Office
- 333 Oyster Point Boulevard
- South San Francisco, CA 94080
- United States
NGM Biopharmaceuticals Timeline
NGM Biopharmaceuticals Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
NGM Biopharmaceuticals Comparisons
Industry
Financing
Details
NGM Biopharmaceuticals Competitors (79)
One of NGM Biopharmaceuticals’s 79 competitors is Astria Therapeutics, a Formerly VC-backed company based in Boston, MA.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Astria Therapeutics | Formerly VC-backed | Boston, MA | ||||
Madrigal Pharmaceuticals | Corporation | West Conshohocken, PA | ||||
Iovance Biotherapeutics | Corporation | San Carlos, CA | ||||
Nimbus Therapeutics | Venture Capital-Backed | Boston, MA | ||||
NexImmune | Formerly VC-backed | Gaithersburg, MD |
NGM Biopharmaceuticals Patents
NGM Biopharmaceuticals Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2023245607-A1 | Ilt3 and cd3 binding agents and methods of use thereof | Pending | 29-Mar-2022 | ||
EP-4499683-A1 | Ilt3 and cd3 binding agents and methods of use thereof | Pending | 29-Mar-2022 | ||
US-20230220076-A1 | Combinational use of an anti-ilt3 antibody and an anti-lair-1 antibody | Pending | 21-Dec-2021 | ||
US-20230107304-A1 | Methods of treating cancer and tumor-related weight loss and cachexia | Inactive | 10-Sep-2021 | ||
AU-2022266780-A9 | Multimerization of binding molecules having an antibody constant region variant | Pending | 28-Apr-2021 | C07K16/18 |
NGM Biopharmaceuticals Signals
NGM Biopharmaceuticals Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
NGM Biopharmaceuticals FAQs
-
When was NGM Biopharmaceuticals founded?
NGM Biopharmaceuticals was founded in 2008.
-
Where is NGM Biopharmaceuticals headquartered?
NGM Biopharmaceuticals is headquartered in South San Francisco, CA.
-
What is the size of NGM Biopharmaceuticals?
NGM Biopharmaceuticals has 158 total employees.
-
What industry is NGM Biopharmaceuticals in?
NGM Biopharmaceuticals’s primary industry is Drug Discovery.
-
Is NGM Biopharmaceuticals a private or public company?
NGM Biopharmaceuticals is a Private company.
-
What is NGM Biopharmaceuticals’s current revenue?
The current revenue for NGM Biopharmaceuticals is
. -
How much funding has NGM Biopharmaceuticals raised over time?
NGM Biopharmaceuticals has raised $122M.
-
Who are NGM Biopharmaceuticals’s investors?
The Column Group has invested in NGM Biopharmaceuticals.
-
Who are NGM Biopharmaceuticals’s competitors?
Astria Therapeutics, Madrigal Pharmaceuticals, Iovance Biotherapeutics, Nimbus Therapeutics, and NexImmune are some of the 79 competitors of NGM Biopharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »